Agios Pharma (AGIO), Celgene (CELG) Enter IDH Mutations Identification Collaboration with Abbott (ABT)

October 12, 2016 7:31 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Celgene Corporation (Nasdaq: CELG) and Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) announced each company has entered into collaboration agreements with Abbott (NYSE: ABT), a leader in diagnostic technologies, to develop and commercialize companion diagnostic tests on Abbott’s m2000 RealTime System to identify isocitrate dehydrogenase (IDH) mutations in acute myeloid leukemia (AML) patients. Celgene is currently developing enasidenib (AG-221/CC-90007), an IDH2 mutant inhibitor, for the treatment of patients with relapsed or refractory AML who have an IDH2 mutation. Agios is developing AG-120, an IDH1 mutant inhibitor, for the treatment of patients with relapsed or refractory AML who have an IDH1 mutation.

IDH1 and IDH2 mutations occur in approximately 20% of AML patients. An article published online this week in the journal Leukemia (Medeiros, Leukemia 2016) concluded that advances in the understanding of the genetics underlying myeloid malignancies are driving an era of development for targeted treatments such as IDH mutant inhibitors. The authors recommend that IDH mutational analysis should become part of the routine AML diagnostic workup and repeated at relapse to identify patients who may be eligible for targeted investigational treatments currently under clinical study.

“AML is a complex and heterogeneous disease, making it difficult to treat,” said Han Myint, M.D., Vice President, Global Medical Affairs, Myeloid for Celgene. “IDH mutations lead to aberrant DNA methylation, causing a block in myeloid differentiation that leads to disease progression. Molecular profiling is important to identify genomic mutations which may have prognostic and potential treatment implications for patients with AML.”

Abbott’s m2000rt RealTime System, is a polymerase chain reaction (PCR) instrument designed to enable clinical laboratories to automate PCR and results analysis, simplifying the complex and manual steps often associated with molecular diagnostics. Both Celgene and Agios have incorporated this screening into clinical trial designs, including the recently initiated Phase 3 IDHENTIFY trial comparing enasidenib with conventional therapy in older patients with an IDH2 mutation and relapsed or refractory AML (NCT02577406).

“The field of personalized medicine is advancing at a rapid pace for a broad range of medical conditions, especially within hematology-oncology,” said Chris Bowden, M.D., chief medical officer at Agios. “Our collaboration with Abbott will provide a test to help identify AML patients with IDH mutations who are in need of treatment options.”

The m2000 system has not been FDA cleared or approved for use with enasidenib or AG-120.

Enasidenib and AG-120 have not been approved for any use in any country.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments


Rhod Minster on 2016-10-13 08:10:33
Mark as Spam | Reply to this comment

Rhod Minster is my name, I am really perplexed today, and I share this piece of good news with everyone reading. Brethren, I was diagnosed of shingles some months after I did a surgery, and I was having serious acute, painful inflammation of the nerve ganglia, with a skin eruption. It was very bad that my skin was gone, and I was almost giving up. The fact was I am very vulnerable because of my weak immune system. So this shingles really affected me. I was taking antiviral medicines after some time it got worst that I was diagnosed of post-herpetic neuralgia. And my doctor prescribed for me paracetamol and codeine which I was using but my condition was getting worst instead of getting better. Somehow, my grandson came home and said his girlfriend was cured of HSV by a herbal doctor whose name was given as Herbal Doctor Uwadia Amenifo. My grandson claimed that his girlfriend was cured by the said doctor with his herbal medicine, so he advised me to give this same herbal doctor a try. I remembered a word at that stage which says ‘there is no harm in trying’ so I decided to give this herbal doctor a try. My grandson help contacted him, and I spoke with him on the phone, and also explained to him in a message I sent to his email. So he assured me, and gave me a good hope that he will surely cure me of this ailment. So we concluded arrangement, and he prepared the herbal medicine, and shipped it to me. So I took it according to his directions. And the herbal mixture really worked for me. I was so surprise the way it worked for me, and in just two weeks, I was beginning to fully recover, and in just less than 2 months, I was fully recovered, and all my pains and inflammation are all gone. Brethren, today I am totally cured and I deem it fit to come here and let everyone know about my cure through the herbal process. Please if you are still suffering from this ailment contact the herbal doctor for your cure. His contact details are as follows Email (, phone number (+2349052015874). Wish you all quick recovery.

Add Your Comment